TY - JOUR
T1 - Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients
T2 - A multicentre cohort study
AU - Sarma, Shohinee
AU - Hodzic-Santor, Benazir
AU - Raissi, Afsaneh
AU - Colacci, Michael
AU - Verma, Amol A
AU - Razak, Fahad
AU - Højbjerg Lassen, Mats C
AU - Fralick, Michael
N1 - Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2024/9
Y1 - 2024/9
N2 - INTRODUCTION: Sodium glucose co-transporter-2 inhibitors (SGLT-2i) are increasingly being used among hospitalized patients. Our objective was to assess the risk of diabetic ketoacidosis (DKA) among hospitalized patients receiving an SGLT-2i.RESEARCH DESIGN AND METHODS: We conducted a multicentre cohort study of patients hospitalized at 19 hospitals. We included patients over 18 years of age who received an SGLT-2i or a dipeptidyl peptidase-4 inhibitor (DPP-4i) in hospital. The primary outcome was the risk of DKA during their hospitalization.RESULTS: 61,517 patients received a DPP-4i and 11,061 received an SGLT-2i. The risk of inpatient DKA was 0.07 % (N = 41 events) among adults who received a DPP-4i and 0.18 % (N = 20 events) among adults who received an SGLT-2i; adjusted odds ratio of 3.30 (95 % CI: 1.85-5.72).CONCLUSIONS: In hospitalized patients, the absolute risk of DKA was 0.2 %, which corresponded to a three-fold higher relative risk.
AB - INTRODUCTION: Sodium glucose co-transporter-2 inhibitors (SGLT-2i) are increasingly being used among hospitalized patients. Our objective was to assess the risk of diabetic ketoacidosis (DKA) among hospitalized patients receiving an SGLT-2i.RESEARCH DESIGN AND METHODS: We conducted a multicentre cohort study of patients hospitalized at 19 hospitals. We included patients over 18 years of age who received an SGLT-2i or a dipeptidyl peptidase-4 inhibitor (DPP-4i) in hospital. The primary outcome was the risk of DKA during their hospitalization.RESULTS: 61,517 patients received a DPP-4i and 11,061 received an SGLT-2i. The risk of inpatient DKA was 0.07 % (N = 41 events) among adults who received a DPP-4i and 0.18 % (N = 20 events) among adults who received an SGLT-2i; adjusted odds ratio of 3.30 (95 % CI: 1.85-5.72).CONCLUSIONS: In hospitalized patients, the absolute risk of DKA was 0.2 %, which corresponded to a three-fold higher relative risk.
KW - Humans
KW - Diabetic Ketoacidosis/epidemiology
KW - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
KW - Male
KW - Female
KW - Middle Aged
KW - Hospitalization/statistics & numerical data
KW - Cohort Studies
KW - Diabetes Mellitus, Type 2/drug therapy
KW - Aged
KW - Adult
KW - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
KW - Risk Factors
KW - Hypoglycemic Agents/adverse effects
UR - http://www.scopus.com/inward/record.url?scp=85200048292&partnerID=8YFLogxK
U2 - 10.1016/j.jdiacomp.2024.108827
DO - 10.1016/j.jdiacomp.2024.108827
M3 - Journal article
C2 - 39096768
SN - 1056-8727
VL - 38
SP - 108827
JO - Journal of Diabetes and its Complications
JF - Journal of Diabetes and its Complications
IS - 9
M1 - 108827
ER -